Kymera in the News
Read about breakthroughs, clinical advancements, and ongoing work to develop new medicines at Kymera.
Featured Perspectives
PharmaVoice: The 2022 PharmaVoice 100 – Nello Mainolfi
Nello Mainolfi, co-founder, president and CEO of Kymera Therapeutics, has an empty prescription bottle on his desk — a bottle that he hopes to soon fill with with one of the biotech company’s drugs.
FastCompany: These innovative projects are changing the health industry
The health category of Fast Company’s World Changing Ideas Awards honors medical innovations that save lives, extend longevity, or increase access to care.
Timmerman Report: Targeted Small Molecule Protein Degraders, Nello Mainolfi on the Long Run
Kymera is working on targeted protein degraders. These are orally available small molecule compounds. Many in biopharma are excited about them because they have a clever design that allows them to go after targets that have previously been out of reach for small molecules. Nello Mainolfi, PhD, Founder, President & CEO shares more about Kymera’s work and mission.